About Gemini Therapeutics
Gemini Therapeutics is a company based in Cambridge (United States) founded in 2015. Gemini Therapeutics has raised $44.5 million across 2 funding rounds from investors including Orbimed, Atlas Venture and Lightstone Ventures. The company has 45 employees as of December 31, 2022. Gemini Therapeutics offers products and services including Therapeutic Pipeline and Precision Medicine Platform. Gemini Therapeutics operates in a competitive market with competitors including Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others.
- Headquarter Cambridge, United States
- Employees 45 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Gemini Therapeutics
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$44.5 M (USD)
in 2 rounds
-
Latest Funding Round
$42.5 M (USD), Series A
Oct 17, 2017
-
Investors
Orbimed
& 2 more
-
Employee Count
45
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Gemini Therapeutics
Gemini Therapeutics offers a comprehensive portfolio of products and services, including Therapeutic Pipeline and Precision Medicine Platform.
Develops targeted therapies for genetically-defined eye diseases.
Identifies genetic variants for disease treatment development.
People of Gemini Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Gemini Therapeutics
Gemini Therapeutics has successfully raised a total of $44.5M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $42.5 million completed in October 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Gemini Therapeutics
Gemini Therapeutics has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Orbimed, Atlas Venture and Lightstone Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm investing in life science and biotechnology sectors
|
Locked | Locked | Locked | |
|
Venture capital fund and fund of funds focused on the life science sector
|
Locked | Locked | Locked | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked |
Investor details for Gemini Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Gemini Therapeutics
Investment portfolio details for Gemini Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Gemini Therapeutics
Detailed financials for Gemini Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Gemini Therapeutics Comparisons
Peer comparison for Gemini Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Gemini Therapeutics
Gemini Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases are developed to treat patients.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Provider of cell therapies to treat cancer and hematologic conditions
|
Detailed competitors of Gemini Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Gemini Therapeutics
Complete news archive for Gemini Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Gemini Therapeutics
Gemini Therapeutics was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Gemini Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Georges Gemayel is the current CEO of Gemini Therapeutics.
Gemini Therapeutics is a funded company, having raised a total of $44.5M across 2 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Gemini Therapeutics is 45.
Gemini Therapeutics was founded in 2015 and is based in Cambridge, United States. The company operates in the biotechnology sector, focusing on precision therapeutics for dry age-related macular degeneration and rare genetic diseases. A genome-driven and multi-modal approach is employed in drug discovery, with treatments targeted to specific genetic mutations and incorporating various modalities rather than a single method.
Gemini Therapeutics's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Gemini Therapeutics offers Therapeutic Pipeline and Precision Medicine Platform.
Gemini Therapeutics has 3 investors. Key investors include Orbimed, Atlas Venture, and Lightstone Ventures.